With $65M in funding, UNC spinout Pinnacle Hill backs professor’s blood cancer research
CHAPEL HILL, N.C. – Researchers at the University of North Carolina at Chapel Hill are one step closer to a possible new treatment against multiple myeloma, a devastating type of blood cancer. That’s because their project now has the backing of Pinnacle Hill, the drug spinout company formed in partnership with UNC and Deerfield Management, a New York-based health care investment firm. The firm recently said it would support a project led by Lindsey Ingerman James, Ph.D., a UNC Eshelman School of Pharmacy chemical biology and medicinal chemistry division...
Read MoreLocus Biosciences to launch major gene editing trial
MORRISVILLE, N.C. – Locus Biosciences, a developer of precision antibacterial therapies, will conduct the world’s first clinical trial of a recombinant bacteriophage therapy, a major milestone for the field, the company announced. Locus has opened enrollment for a Phase 1b trial of a potential treatment for urinary tract infections caused by Escherichia coli (E. coli) bacteria. The study will evaluate LBP-EC01, a bacteriophage “cocktail” that has been engineered with the gene editing technology CRISPR Cas3 to target the E. coli genome. “This trial represents a major...
Read MoreAegle Therapeutics Announces $4M Financing to Fund Groundbreaking Stem Cell Exosome Clinical Trial to Treat Orphan Disease Dystrophic Epidermolysis Bullosa
BOSTON, MA. and MIAMI, FL. – Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal stem cells as therapy, today announced the closing of a $4M financing. Aegle’s platform technology is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder. The investment was led by Boca Raton-based New World Angels, with participation from Tellus BioVentures, DEFTA Healthcare Technologies and DeepWork...
Read MoreScripps Research invites audiences to take a ‘front row’ seat to science when CEO opens new lecture series on Jan. 22
JUPITER, FL – Dec. 16, 2019 – Peter Schultz, PhD, a pioneering chemist and president and CEO of Scripps Research, will kick off the institute’s upcoming Front Row Lecture Series on its Florida campus on Wednesday, Jan. 22 with a presentation on how the institute is helping scientific discoveries reach patients with unmet medical needs. The series, which is free to attend with a reservation, invites audience members to “take a front row seat to history” and learn about the scientific and medical advances arising from Scripps Research—advances that are changing science and...
Read MoreSEBIO Congratulates 2019 Award Winners
Best Deals In Class Award Winners Announced Each year SEBIO recognizes healthcare and life sciences organizations in the Southeastern US whose achievements are bringing the region into focus as a hub of medical and technological innovation. The 2019 Investor & Partnering Forum in Miami honored five very worthy companies from across the region for their accomplishments this year.The awards were presented by Evan McClure, MD, a partner in the Life Sciences practice of global executive search firm Odgers Berndtson. “This community of entrepreneurs continues to produce curative...
Read MoreVENTURE CONNECT SUMMIT LEADERS ANNOUNCED
The Council for Entrepreneurial Development (CED) today announced five leaders for Venture Connect. As Summit leaders, they are leading the strategy for this annual event along with the CED team. “We are thrilled to have such successful, experienced entrepreneurs and leaders providing their expertise to ensure that this event is a major success,” said Ravila Gupta, CED’s President and CEO. The Summit leaders will help bring together the tech and life science worlds with their unique, and expert experience as leaders, CEOs, founders, board members, investors, and...
Read More
Follow Us!